Resistance of enterobacteria to carbapenem antibiotics is a global crisisBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e1646 (Published 06 March 2012) Cite this as: BMJ 2012;344:e1646
- Janice Hopkins Tanne
- 1New York
A large family of Gram negative bacteria, the enterobacteriaceae, are developing resistance to carbapenem antibiotics, a class of β lactam antibiotics that are often antibiotics of last resort, speakers at a New York Academy of Sciences symposium have said. They called it a global crisis.
The problem was greater than that posed by the New Delhi metallo-β-lactamase-1 plasmid (NDM-1), which confers resistance to nearly all the β lactam antibiotics (BMJ 2010;341:c5124, doi:10.1136/bmj.c5124), said the microbiologist Barry Kreiswirth of the Public Health Research Institute at the University of Medicine and Dentistry of New Jersey. “We just don’t have many treatment options: colistin, polymyxin B, tigecycline, and rifampicin,” he said.
David Perlin, executive director of the Public Health Research Institute, said that carbapenemase producing Klebsiella pneumoniae is the most common …